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Background: There is no standard treatment for recurrent thymic 
epithelial tumors. Although the efficacy has not been validated based 
on the large series studies, surgical resection is sometimes employed 
for patients with recurrent thymic tumors. The aim of this study is to 
evaluate the surgical outcomes for recurrent thymic epithelial tumors 
based on the Japanese nationwide database.
Methods: From the database of patients whose thymic epithelial 
tumors were treated surgically from 1991 through 2010, the cohort 
who developed recurrence after the initial resection was extracted. 
Clinicopathological factors were reviewed, and the prognostic factors 
of re-resected cases were examined.
Results: Twenty-eight hundred thirty-five patients who underwent 
surgical resection of thymic epithelial tumors were registered to the 
database. Among these patients, 420 (14.8%) experienced recur-
rence. One hundred sixty-two patients were treated surgically and 
243 were treated nonsurgically for recurrent disease. The 5- and 
10-year postrecurrence survival rates were 82.7% and 68.2%, respec-
tively, in the surgery group and 43.5% and 25.4%, respectively, in 
the nonsurgery group (p < 0.001). According to univariate analyses, 
female sex and the pathological Masaoka I-II stage, nonthymic car-
cinoma, absence of preoperative treatment and longer recurrent-free 
interval (RFI) were significantly favorable factors for survival in the 
surgery group. According to the multivariate analysis, nonthymic 
carcinoma histology and longer RFI were identified to be indepen-
dent prognostic factors.
Conclusions: The surgical outcomes of recurrent thymic epithelial 
tumors are favorable in selected patients. The role of re-resection 
may be limited in the setting of thymic carcinoma and/or a short RFI.
Key Words: Recurrent thymic epithelial tumors, Thymic cancer, 
Thymoma, Surgical resection, Disease-free interval.
(J Thorac Oncol. 2015;10: 199–205)
Thymic epithelial tumors are rare neoplasms, reported to account for 50% of the anterior mediastinal masses. In 
particular, the incidence of thymomas, which comprise a 
major portion of thymic epithelial tumors, is 0.15 per 100,000 
person-years.1–3 Tumors of this entity exhibit a heteroge-
neous malignant potential with progression, and clinicians 
often encounter long-term survivors who experience recur-
rence after the initial complete resection. Recurrence is often 
observed at local, regional, or distant sites in patients with 
other malignancies, including lung cancer. However, surgi-
cal resection of recurrent lesions is employed as a treatment 
option in such patients, although the efficacy and indications 
have not been elucidated. One possible reason for the lack of 
data regarding this issue is the rarity of these tumors, with only 
small series being evaluated in previous reports. Accordingly, 
an analysis of this issue in a large cohort is required.
The aim of this study was to analyze the outcomes of 
patients with thymic epithelial tumors who were surgically 
treated for recurrent disease after the initial resection and 
discuss the contribution of surgical intervention for recurrent 
disease based on the data found in the Japanese nationwide 
database.
MATERIALS AND METHODS
A Japanese nationwide registry study of thymic epithe-
lial tumors was carried out by the Japanese Association for 
Research on the Thymus. The medical data of 2835 patients 
with thymic epithelial tumors treated surgically during the 
period from 1991 through 2010 were retrospectively col-
lected and registered from 32 Japanese institutes. Seventy-
eight variables, including patient demographics, clinical 
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diagnosis, surgical procedure, pathological diagnosis, periop-
erative therapy and outcomes, were investigated. With regard 
to diagnosis of recurrence, the follow-up schedule and the 
introduced modalities depended on the respective institutions. 
The histological diagnoses were made according to the World 
Health Organization (WHO) classification of thymic epithe-
lial tumors, and the stage of disease was determined based on 
the revised Masaoka staging system.1,4
In the present study, 420 patients who experienced recur-
rence after the initial resection were extracted from the entire 
cohort, as records concerning recurrence were not complete 
in 194 patients. Recurrence was defined as the clinical detec-
tion of new lesions after complete resection of the primary 
tumor and as the detection of new lesions and progression of 
residual diseases after incomplete resection. Fifteen patients 
without information regarding the presence of redo surgery 
were excluded to investigate the contribution of surgery to the 
survival of patients with recurrence.
Recurrence-free interval (RFI) was defined as the dura-
tion between the date of initial surgery for the primary tumor 
and the date of detection of recurrence. Postrecurrent survival 
time was calculated from the date of diagnosis of recurrence 
to the date of either death or the last follow-up. Categorical 
variables in each group were compared using the χ2 test or 
Fischer’s exact test. Survival curves were created according to 
the Kaplan–Meier method, with differences examined using 
the log-rank test. A multivariate analysis of prognostic factors 
in the re-resected cases was performed using a Cox propor-
tional hazard model. The statistical analyses were carried out 
using the SPSS software package for Windows (version 12.0; 
Chicago, IL). In both the univariate and multivariate analyses, 
a p value of less than 0.05 was considered to be significant. 
This nationwide registry study was approved by the institu-
tional review board of each participating institution, including 
Nagoya University Hospital.
RESULTS
The median follow-up period after diagnosis of recur-
rence was 59.8 months among all 405 patients and 73.3 
months among the 267 surviving patients.
The patient demographics are shown in Table 1. The 
mean age of the patients at the time of initial resection was 
54.8 years. The majority of the patients had advanced disease 
of stage III or IV (n = 329; 81.2%) and tumors of type B3 
thymoma or a carcinoma histology (n = 235; 58.0%), which 
usually represented an aggressive behavior. The initial resec-
tion resulted in R0 in 254 patients (62.7%). A repeated resec-
tion was performed in 162 patients (40.0%) for recurrent 
disease (surgery group), whereas the remaining 243 patients 
(60.0%) were treated nonsurgically (nonsurgery group). In 
the nonsurgery group, 42 patients received chemoradiother-
apy, 75 received chemotherapy, and 77 received radiotherapy 
for their recurrent disease. Ninety-one patients received 
 supportive care.
Comparing the patient demographics of the surgery 
and nonsurgery groups, the mean age of the patients was 
lower in the surgery group (p = 0.408). The distribution of 
the WHO histologic classification also differed between the 
two groups (p < 0.001); more patients with a carcinoma his-
tology were included in the nonsurgery group. Preoperative 
adjuvant therapy was introduced in the initial treatment regi-
men more frequently in the nonsurgery group (37.4% versus 
25.9%, p = 0.017). Postoperative adjuvant therapy was also 
introduced more frequently in the nonsurgery group (27.6% 
versus 20.3%, p = 0.126). Fifty-three of 149 patients (35.6%) 
with incomplete resection at initial surgery received that treat-
ment. In terms of the completeness of the initial surgery, a 
superior success rate was observed in the surgery group than 
in the nonsurgery group. Seventy-two percent of the patients 
underwent complete resection in the surgery group, whereas 
56.8% of the patients received this treatment in the nonsur-
gery group. The RFI after the initial resection was longer in 
the surgery group than in the nonsurgery group, at 3.2 and 2.2 
years, respectively (p < 0.001).
The most frequent metastatic site was the pleura, in 
which 219 patients (54.1%) experienced disease recurrence, 
followed by the lungs (21.0%) and the local sites (17.3%). 
The prevalence of metastasis to the bone and liver was signifi-
cantly higher in the nonsurgery group. In the surgery group, 
more patients exhibited recurrence in the pleura, which was 
considered to be a favorable indication for resection. On 
the other hand, a limited number of patients, including four 
patients with bone metastasis, two patients with liver metasta-
sis and one patient with brain metastasis, underwent surgical 
resection for recurrence (Table 1). Regarding the number of 
metastatic sites, a large portion of the patients (90.7%) devel-
oped single-site recurrence in the surgery group, compared 
with 76.1% of the patients in the nonsurgery group. Among 
the 147 patients with single-site recurrence in the surgery 
group, 85 (57.8%) exhibited pleural dissemination, followed 
by 24 (16.3%) with pulmonary metastasis and 20 (13.6%) 
with local disease.
The 5- and 10-year survival rates of all patients with 
recurrence were 59.9% and 42.5%, respectively (Fig. 1A). 
According to histology, the 5- and 10-year survival rates of 
thymoma patients were 76.2% and 50.0%, respectively, and 
those of thymic carcinoma patients were 30.8% and 28.2%, 
respectively (p < 0.001) (Fig. 1B). Although prevalence of re-
resection was less frequent in Type B2-3 thymoma compared 
with Type A-B1 thymoma (47.6% versus 56.9%, p = 0.231), 
the WHO histological classification of thymoma did not dem-
onstrate any significant trends with respect to the survival 
outcomes. The survival of the surgery group was significantly 
better than that of the nonsurgery group, with 5- and 10-year 
survival rates of 82.7% and 68.2%, respectively, in the sur-
gery group and 43.5% and 25.4%, respectively, in the non-
surgery group (p < 0.001) (Fig. 2A). The trend that survival 
of the surgery group was significantly better than those with 
the nonsurgery group was also observed in subgroup analy-
ses according to the completeness of initial resection for the 
primary tumor (Fig. 2B, C). According to a subgroup analysis 
of the thymoma and thymic carcinoma cases, the superiority 
of survival of the surgery group over the nonsurgery group 
remained for each histology (p < 0.001, p = 0.018, respec-
tively). In addition, an analysis of the completeness of re-
resections showed a survival advantage among the patients 
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treated with R0-1 and R2 re-resections compared with that 
observed in the nonsurgery group (p < 0.001, p = 0.004) 
(Fig. 3A). A significant survival advantage was also noted 
among the patients treated with R0-1 re-resection com-
pared with that observed in the nonsurgery group for each 
histology (p < 0.001, p = 0.014) (Fig. 3B, C). Meanwhile, 
the survival of the patients treated with R2 re-resection was 
intermediate between that of the patients treated with R0-1 
re-resection and that observed in the nonsurgery group for 
thymomas, although the difference between the patients 
treated with R2 re-resection and the nonsurgery group was 
not significant for either histology (p = 0.143 and 0.809, 
respectively). The results of the univariate analyses and 
estimated postrecurrence survival rates of the surgery group 
according to each variable are presented in Table 2. These 
analyses demonstrated that female sex and the Masaoka I-II 
stage, nonthymic carcinoma, use of preoperative treatment 
and longer RFI (≥3 years) were significant prognostic factors 
in the surgery group, whereas the completeness of re-resec-
tion was not identified to be a significant factor (p = 0.385). 
Regarding the patients with single-site recurrence, the 5- and 
10-year survival rates of the patients with pleural dissemina-
tion were 90.6% and 66.9%, respectively, which indicated a 
trend toward a more favorable survival compared with that 
observed in the patients with recurrence at the other sites 
(data not shown).
TABLE 1.  Patients Demographics
Variables
Total NonSurgery Surgery
p405 % 243 % 162 %
Age (year) 54.8 ± 13.9 57.1 ± 13.5 51.4 ± 13.9 0.408
Sex (male/female) 220/185 53.0/47.0 139/104 57.2/42.8 81/81 50.0/50.0 0.156
Masaoka stage <0.001
  I 22 5.4 6 2.5 16 9.9
  II 53 13.1 20 8.2 33 20.4
  III 153 37.8 91 37.4 62 38.3
  IVa 105 25.9 71 29.2 34 20.9
  IVb 71 17.5 55 22.7 16 9.9
  Unknown 1 0.3 0 0 1 0.6
Histologic type <0.001
  A 7 1.7 3 1.2 4 2.5
  AB 14 3.5 7 2.9 7 4.3
  B1 37 9.1 15 6.2 22 13.6
  B2 106 26.2 54 22.2 52 32.1
  B3 79 19.5 43 17.7 36 22.2
  Cancer 156 38.5 118 48.6 38 23.5
  Others 6 1.5 3 1.2 3 1.8
Myasthenia gravis 54 13.3 24 9.9 30 18.5 0.017
Preoperative treatment 133 32.8 91 37.4 42 25.9 0.017
Postoperative treatment 100 24.7 67 27.6 33 20.3 0.126
Postrecurrence nonsurgical treatment 241 59.5 152 62.6 89 54.9 0.126
Completeness of the initial surgery 0.009
  R0 254 62.7 138 56.8 116 71.6
  R1 64 15.8 44 18.1 20 12.3
  R2 85 20.9 60 24.7 25 15.4
Unknown 2 0.6 1 0.4 1 0.7
Recurrent-free interval (year) 2.7 ± 2.3 2.2 ± 2.4 3.2 ± 2.8 <0.001
No. of recurrent sites 1.3 ± 0.7 1.4 ± 0.7 1.3 ± 0.7 0.165
Recurrent site
  Local 70 17.3 44 18.1 26 16.0 0.688
  Pleura 219 54.1 132 54.3 97 59.9 0.067
  Pericardium 9 2.2 7 2.9 2 1.2 0.326
  Lung 85 21.0 53 21.8 32 19.8 0.709
  Bone 26 6.4 22 9.1 4 2.5 0.007
  Liver 15 3.7 13 5.3 2 1.2 0.033
  Brain 5 1.2 4 1.6 1 0.6 0.652
  Others 60 14.8 44 18.1 16 9.9 0.023
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With regard to the extrathoracic metastases including 
those in the bone, liver, and brain, we identified six patients 
who underwent resection for their recurrences. Postrecurrence 
survival of them ranged from 0.7 to 4.8 years. Four patients 
were alive with disease, one was alive without disease, and 
one died of disease.
Furthermore, the multivariate analysis showed the WHO 
histologic type (nonthymic carcinoma) and longer RFI to be 
favorable prognostic factors in the patients who underwent 
surgery for recurrent disease (Table 3).
DISCUSSION
Thymic epithelial tumors are rare neoplasms, with 
recurrence after resection observed in 7% to 22.3% of the 
patients.5–7 Our rate of 14.8% among the entire cohort is con-
sistent with the findings of the previous reports. It has been 
demonstrated that the proportion of patients exhibiting recur-
rence is increased among those with advanced thymoma. For 
example, 5% to 10% of the patients with stage I or II disease 
experience recurrence, whereas this proportion is elevated, at 
approximately 30%, among those with more advanced stages 
of the disease.8 Okumura et al.9 reported that the incidence of 
tumor recurrence is closely correlated with the WHO histo-
logic type of thymoma, which reflects the oncologic nature of 
the tumor; that is, the authors documented failure of surgical 
treatment in as many as 28.6% of the patients with resected 
type B3 thymoma. Thymic carcinoma is known to exhibit a 
more aggressive behavior and is considered to be a distinct 
subtype to thymoma, with recurrence reported in more than 
half of the affected patients.5
To date, several reports, including small series, have 
documented the outcomes of surgical management of recur-
rent thymic epithelial tumors. However, the efficacy of this 
modality remains controversial. In the present study, we aimed 
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to examine the surgical outcomes of treatment for recurrent 
thymic epithelial tumors based on a large cohort recruited 
from the Japanese nationwide database. Most previous reports 
have supported the presence of an association between surgi-
cal resection and survival as a treatment for recurrent thymic 
tumors compared with that observed in nonsurgical cases. For 
example, Margaritora et al.10 showed a significant survival 
difference between patients treated with repeated surgery and 
those treated without surgery among subjects with recurrent 
thymoma, with 5-year survival rates of 77% and 35%, respec-
tively. Bott et al.7 also recently reported 5-year survival rates of 
surgery and nonsurgery cases of 82% and 58%, respectively. 
TABLE 2.  Univariate Analysis of Prognostic Factors in Patients with Resected Recurrent Thymic Tumors
Variables n = 162 Five-Year Survival (%) Ten-Year Survival (%) p
Sex
  Male 81 74.6 60.4 0.036
  Female 81 90.5 76.7
Age
  <50 65 86.7 59.3 0.525
  ≥50 92 78.8 69.6
Masaoka stage
  I–II 49 89.5 89.5 0.033
  III–IV 112 79.3 56.7
  Unknown 1
Histologic type
  A–B3 121 92.0 73.7 < 0.001
  Cancer 38 53.4 44.5
  Others 3
Myasthenia gravis
  Present 30 95.6 86.1 0.292
  Absent 132 79.6 65.3
Preoperative treatment
  Present 42 73.4 51.5 0.025
  Absent 120 85.8 75.3
Postoperative treatment
  Present 88 77.6 62.1 0.097
  Absent 74 85.8 80.5
Postrecurrence nonsurgical treatment
  Present 33 77.6 62.1 0.097
  Absent 129 91.2 80.5
Completeness of the initial surgery
  Complete (R0) 115 84.4 68.7 0.565
  Incomplete (R1-2) 45 78.0 64.0
  Unknown 1
Recurrent-free interval (year)
  <3 92 76.9 55.6 0.012
  ≥3 65 90.3 90.3
  Unknown 5
No. of recurrent sites
  One 147 84.3 68.1 0.219
  Two or more 15 70.1 —
Re-reresection
  Present 43 82.0 82 0.421
  Absent 114 83.5 61.6
  Unknown 5
Completeness of re-resection
  R0-1 116 82.5 64.1 0.385
  R2 39 79.7 62.1
  Unknown 7
204 Copyright © 2014 by the International Association for the Study of Lung Cancer
Mizuno et al. Journal of Thoracic Oncology ®  •  Volume 10, Number 1, January 2015
Although the potential contribution of repeated resection for 
recurrent thymic tumors was suggested in these reports, the 
authors also emphasized the importance of patient selection. 
On the other hand, Haniuda et al.11 did not find any signifi-
cant survival benefits of repeated resection, reporting a 5-year 
survival rate of 46.9% among patients treated with repeated 
resection, which is lower than that of other reports. In their 
study, the authors referred to their low complete resection 
rate of 27% for recurrent disease and the possible inclusion of 
patients with a poor prognosis. In the present study, the 5- and 
10-year survival rates were 82.7% and 68.2%, respectively, in 
the surgery group and 43.5% and 25.4%, respectively, in the 
nonsurgery group, which also supports the finding of improved 
survival among selected patients treated with repeated resec-
tion. As shown in Table 1, the patient demographics differed 
according to the Masaoka stage, WHO histological type, 
presence of MG, use of preoperative treatment and complete-
ness of the initial surgery between the two groups. Although 
these differences may reflect the effects of patient selection 
with respect to the indications for repeated resection, we were 
unable to identify such candidates clearly due to our study 
design, which was based on the retrospective database.
In the present study, we demonstrated the survival 
advantage of re-resected thymic tumor, even in the patients 
with R2 re-resection of recurrent disease. Although survival 
of patients with R0-1 re-resection seemed to be slightly better 
than that with R2 re-resection, we did not detect a statisti-
cal difference as presented in Figure 3A. However, survival 
of the patients with R0-1 re-resection was significantly better 
than that with R2 re-resection, survival of patients treated with 
R2 resection was intermediate between R0-1 and nonsurgery 
in thymoma cases. We consider that these results suggested 
potential efficacy of debulking in thymoma cases, and not in 
thymic carcinoma cases. These biological differences between 
the two entities of the tumor and the small sample size might 
lead to failure in detecting statistical difference in the whole 
recurrent cases. We herein identified the nonthymic carcinoma 
histology and longer RFI to be the favorable prognostic factors 
among the patients with resected recurrent thymic epithelial 
tumors. Meanwhile, a comparison of patterns of recurrence 
of thymoma and thymic cancer revealed some differences 
between these two groups.12 For example, thymic carcinoma 
presents more frequently with distant failure in addition to a 
shorter RFI and earlier onset of recurrence than thymoma, 
which appears to confirm the more aggressive nature of thymic 
carcinoma. Hamaji et al.13 also found the WHO histology to 
be a significant prognostic factor after recurrence in a study of 
48 patients with recurrent disease. In that report, the authors 
suggested that surgical management is associated with bet-
ter survival rates among patients with recurrent thymoma, 
although the role of this modality is limited in those with thy-
mic carcinoma. Our current results seem to support their con-
clusion, and therefore, careful patient selection, especially in 
cases of thymic carcinoma, is required.
Although RFI is generally considered to be a predictive 
factor of survival among patients with recurrent malignancies, 
several reports have failed to prove a significant association 
between RFI and survival in thymic epithelial tumors. One rea-
son for the previous results is thought to be brought about by 
the small number of each study, which may be associated with 
a poor statistical power to detect significant differences.11,14,15 
Biologically, this factor may represent a phenotype of less 
aggressive thymic tumors.
As to the site of recurrence, more than half of the resected 
patients evaluated in this study experienced recurrence in the 
pleura, which was also the most frequent metastatic site. Limited 
to the cases of single-site recurrence, this site accounted for 
57.8% of the cases (85 of 147 patients), with a favorable sur-
vival among the resected cases. Although there is currently no 
standard treatment for pleural recurrence, repeated resection is 
considered to be an acceptable option. According to a report 
by Lucchi et al.16, the resection of pleural metastases may thus 
make it possible to achieve paraneoplastic syndrome control in 
addition to improving the survival outcome.
Due to the study design based on the retrospective data-
base, our study includes several limitations. First, our study 
cannot exclude selection bias completely, and it subsequently 
led to the subtraction of patients with better prognosis for 
surgery case and to heterogeneous diagnosis of progression, 
which means that the modality used in the diagnoses of recur-
rence and the definition of recurrence may depend on the 
respective institutions. The lack of central pathology review 
may be also another limitation. It is well known that the dis-
tinction between thymic carcinoma and B3 thymona is chal-
lenging even for expert pathologists in diagnosis of thymic 
tumors. We should also remind that the pathological diagnoses 
in our study may impact our results strongly.
In conclusion, we demonstrate the survival advantages 
of patients who underwent surgical treatment for the recurrent 
lesions from thymic epithelial tumors, in comparison with the 
survival outcome obtained in patients treated nonsurgically. 
Therefore, re-resection can be indicated for selected patients 
in the management of recurrent disease after the initial surgi-
cal treatment for thymic epithelial tumors.
TABLE 3.  Multivariate Analysis of Prognostic Factors in Patients with Resected Recurrent Thymic Epithelial Tumors
Variables Reference HR 95% CI p
Sex (male) Female 1.92 0.801–4.585 0.144
Stage (I–II) Stage III–IV 0.64 0.199–2.085 0.463
Histologic type (thymic carcinoma) Others 3.23 1.392–7.518 0.006
Preoperative treatment (present) Absent 1.657 0.695–3.951 0.255
Recurrent-free interval 0.744 0.565–0.979 0.035
HR, hazard ratio; CI, confidence interval.
205Copyright © 2014 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology ®  •  Volume 10, Number 1, January 2015 Surgical Management of Recurrent Thymic Epithelial Tumors
However, the efficacy of this modality is limited 
in patients with thymic carcinoma and/or a short RFI. 
Therefore, a multimodal approach should be considered in 
such cases.
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